Healthcare provider profile · identity verified

Peter Agho, MD

Family Practice · BRONX, NY · NPI 1316020068

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	458	147
Albuterol Sulfate Hfa	Albuterol Sulfate	255	78
Metoprolol Succinate	Metoprolol Succinate	236	76
Metformin Hcl	Metformin Hcl	224	65
Amlodipine Besylate	Amlodipine Besylate	216	74
Lisinopril	Lisinopril	155	48
Pantoprazole Sodium	Pantoprazole Sodium	149	50
Gabapentin	Gabapentin	140	51
Ozempic	Semaglutide	133	34
Losartan Potassium	Losartan Potassium	132	47
Vitamin D2	Ergocalciferol (Vitamin D2)	130	49
Eliquis	Apixaban	126	36
Levothyroxine Sodium	Levothyroxine Sodium	120	37
Pioglitazone Hcl	Pioglitazone Hcl	118	36
Simvastatin	Simvastatin	106	35
Hydrochlorothiazide	Hydrochlorothiazide	105	37
Furosemide	Furosemide	99	39
Januvia	Sitagliptin Phosphate	97	29
Tamsulosin Hcl	Tamsulosin Hcl	91	32
Montelukast Sodium	Montelukast Sodium	88	35
Ibuprofen	Ibuprofen	82	36
Omeprazole	Omeprazole	82	26
Fluticasone Propionate	Fluticasone Propionate	80	32
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	80	27
Nifedipine Er	Nifedipine	70	21
Meclizine Hcl	Meclizine Hcl	67	22
Naproxen	Naproxen	66	21
Telmisartan	Telmisartan	64	20
Carvedilol	Carvedilol	63	25
Ezetimibe	Ezetimibe	62	19
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	60	20
Jardiance	Empagliflozin	59	23
Prednisone	Prednisone	57	45
Rosuvastatin Calcium	Rosuvastatin Calcium	56	23
Mirtazapine	Mirtazapine	54	15
Albuterol Sulfate	Albuterol Sulfate	46	33
Lorazepam	Lorazepam	45	18
Metoprolol Tartrate	Metoprolol Tartrate	45	15
Donepezil Hcl	Donepezil Hcl	43	14
Alendronate Sodium	Alendronate Sodium	42	13
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	41	15
Sertraline Hcl	Sertraline Hcl	41	14
Bupropion Xl	Bupropion Hcl	39	13
Ketoconazole	Ketoconazole	38	18
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	38	14
Allopurinol	Allopurinol	37	14
Clopidogrel	Clopidogrel Bisulfate	36	14
Single Use Swab	Alcohol Antiseptic Pads	35	15
Trazodone Hcl	Trazodone Hcl	34	16
Enalapril Maleate	Enalapril Maleate	33	suppressed
Famotidine	Famotidine	33	12
Alprazolam	Alprazolam	30	14
Glimepiride	Glimepiride	30	suppressed
Telmisartan-Hydrochlorothiazid	Telmisartan/Hydrochlorothiazid	30	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	29	suppressed
Spironolactone	Spironolactone	28	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	27	12
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	27	suppressed
Oxycodone Hcl	Oxycodone Hcl	27	suppressed
Pravastatin Sodium	Pravastatin Sodium	27	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	27	12
Bupropion Hcl Sr	Bupropion Hcl	26	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	25	11
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	25	suppressed
Glipizide Er	Glipizide	25	suppressed
Meloxicam	Meloxicam	24	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	24	12
Levetiracetam	Levetiracetam	23	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	22	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	22	12
Potassium Chloride	Potassium Chloride	22	suppressed
Ammonium Lactate	Ammonium Lactate	21	11
Atenolol	Atenolol	21	suppressed
Novolog Flexpen	Insulin Aspart	21	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	21	suppressed
Valsartan	Valsartan	21	suppressed
Finasteride	Finasteride	20	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	19	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	18	17
Clonazepam	Clonazepam	18	suppressed
Diclofenac Sodium	Diclofenac Sodium	18	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	18	suppressed
Megestrol Acetate	Megestrol Acetate	17	suppressed
Azithromycin	Azithromycin	16	14
Duloxetine Hcl	Duloxetine Hcl	16	suppressed
Entresto	Sacubitril/Valsartan	16	suppressed
Tramadol Hcl	Tramadol Hcl	16	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	15	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	15	11
Glipizide	Glipizide	15	suppressed
Rybelsus	Semaglutide	15	suppressed
Synthroid	Levothyroxine Sodium	15	suppressed
Ibu	Ibuprofen	14	suppressed
Ranolazine Er	Ranolazine	14	suppressed
Vascepa	Icosapent Ethyl	14	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	13	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	13	suppressed
Fenofibrate	Fenofibrate	13	suppressed
Hydralazine Hcl	Hydralazine Hcl	13	suppressed
Tresiba Flextouch U-100	Insulin Degludec	13	suppressed
Breo Ellipta	Fluticasone/Vilanterol	12	suppressed
Clindamycin Phosphate	Clindamycin Phosphate	12	suppressed
Labetalol Hcl	Labetalol Hcl	12	suppressed
Topiramate	Topiramate	12	suppressed
Tradjenta	Linagliptin	12	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	11	suppressed
Citalopram Hbr	Citalopram Hydrobromide	11	suppressed
Farxiga	Dapagliflozin Propanediol	11	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	11	suppressed
Lansoprazole	Lansoprazole	11	suppressed
Lidocaine	Lidocaine	11	suppressed
Lovastatin	Lovastatin	11	suppressed
Metformin Hcl Er	Metformin Hcl	11	suppressed
Torsemide	Torsemide	11	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	11	suppressed
Varenicline Tartrate	Varenicline Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error